Thursday, August 1, 2013
Pacira Pharma pain drug fails late-stage trial
(Reuters) - Pacira Pharmaceuticals Inc said its lead drug did not meet the main goal in a late-stage trial of reducing pain for patients undergoing a surgical procedure called posterolateral thoracotomy.
Pacira said the company did not meet the main goal of reducing pain scores over 72 hours, compared with a placebo.
The results are from a second late-stage study of the drug, Exparel, which is already approved as a single-dose injection to treat postsurgical pain.
(Reporting By Vrinda Manocha in Bangalore; Editing by Maju Samuel)
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers. Five Filters recommends: 'You Say What You Like, Because They Like What You Say' - http://www.medialens.org/index.php/alerts/alert-archive/alerts-2013/731-you-say-what-you-like-because-they-like-what-you-say.html
